医药生物行业周报：产业链体系持续完善、板块业绩回暖在望，关注中药高质量发展-20260226

Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights the approval of Novartis' siRNA lipid-lowering drug for new indications in China, emphasizing the focus on the PCSK9 and small nucleic acid sectors [3]. - Mergers and acquisitions, along with licensing collaborations, remain active, accelerating resource integration in the innovative drug field [3]. - The development of brain-computer interfaces is entering a fast track, with the industrialization process accelerating [3]. - The Chinese herbal medicine industry is expected to experience a recovery in performance, with a focus on high-quality development [3]. Summary by Relevant Sections Industry Development - The Ministry of Industry and Information Technology and seven other departments released the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)," aiming to optimize the structure and upgrade the traditional Chinese medicine industry [5]. - By 2030, a collaborative development system for the entire traditional Chinese medicine industry chain is expected to take shape, with significant improvements in quality and efficiency [5]. - The plan includes six key tasks with 15 specific actions, such as enhancing raw material quality, promoting collaborative innovation, and modernizing the national medicine industry [5]. Performance Recovery - The report indicates a performance recovery trend in the traditional Chinese medicine sector, with companies like Teva Pharmaceutical expecting a net profit of 70 million to 90 million yuan in 2025, representing a year-on-year increase of 241.55% to 339.13% [5]. - Yiling Pharmaceutical forecasts a turnaround with a net profit of 1.2 billion to 1.3 billion yuan, compared to a loss of 725 million yuan in 2024 [5]. - Other companies, such as Huaren Jiangzhong and Zhongsheng Pharmaceutical, also project significant profit increases for 2025, indicating a positive outlook for the sector [5]. Investment Recommendations - The report suggests that the traditional Chinese medicine industry is likely to continue its transformation and upgrade, with improved resilience and stability in the supply chain [6]. - It recommends focusing on companies such as Zhongsheng Pharmaceutical, Teva Pharmaceutical, Yiling Pharmaceutical, and Huaren Jiangzhong as potential investment opportunities [6].